Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06600724 · ClinicalTrials.gov registry record · NA

Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs

A NA study of Diabetic Foot Ulcer and Diabetic Foot, sponsored by MiMedx Group.

Recruiting
Registry status
NA
Development phase
170
Enrollment target
1
Study location

NCT06600724 is a NA study of Diabetic Foot Ulcer and Diabetic Foot that is actively recruiting participants, run by MiMedx Group. The registered enrollment target is 170 participants, below the 252-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06600724, a NA study of Diabetic Foot Ulcer and Diabetic Foot, is actively recruiting participants, sponsored by MiMedx Group.

RECRUITING
Registry status
NA
Development phase
170 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).

Interventions

  • OTHER Standard of Care
  • OTHER EPIEFFECT
  • OTHER EPIXPRESS

Study Locations (1)

Pennsylvania

  • SerenaGroup - Monroeville - Monroeville

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2024-08-27
Est. Completion 2026-08
Phase NA

Sponsor

MiMedx Group

32 total trials

What the Registry Record Tells You About NCT06600724

The ClinicalTrials.gov registry entry for NCT06600724 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (33% lower). The listed sponsor is MiMedx Group, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.

NCT06600724 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06600724 about?

NCT06600724 is a clinical study titled "Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs". This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).

What is the current status of trial NCT06600724?

This trial is currently recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2024-08-27. Estimated completion is 2026-08.

What conditions does trial NCT06600724 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer, Foot Ulcer, Diabetic, Foot Ulcer Due to Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT06600724?

The interventions under investigation include: Standard of Care (OTHER), EPIEFFECT (OTHER), EPIXPRESS (OTHER).

Who is sponsoring clinical trial NCT06600724?

This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06600724 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.